Lausanne, Switzerland-based AC Immune SA thinks the best potential for treating Parkinson’s disease and other neurodegenerative diseases lies in prevention, using a combination of therapeutic vaccines and diagnostics that can distinguish one proteinopathy from another.
In a recent interview with In Vivo, CEO Andrea Pfeifer explained why recent advancement with alpha-synuclein PET tracer ACI-12589 offers the potential to unlock new approaches to Parkinson’s, Alzheimer’s disease,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?